Side-effect deep dive
Gallbladder issues on GLP-1 medications
Rapid weight loss elevates gallstone risk regardless of drug. STEP-1 reported 2.6% incidence vs 1.2% placebo. Mitigation: gradual weight loss + maintained dietary fat.
Why it happens
Rapid weight loss + reduced bile flow + altered cholesterol saturation creates the classic gallstone-formation environment. This is a weight-loss-mediated risk, not a GLP-1-specific risk.
How to manage it
- 1.Gradual weight loss (β€1-2 lb/week)
- 2.Maintain protein intake to preserve gallbladder emptying
- 3.Some dietary fat in meals β very-low-fat diets accelerate stone formation
- 4.Stay hydrated
When to call your prescriber
- Persistent right-upper-quadrant pain
- Pain after fatty meals lasting hours
- Jaundice (yellowing of skin or eyes)
- Fever + abdominal pain
Affected medications
Sources
People also ask
Common questions readers ask
- Does Ozempic cause hair loss?
- Not directly. Hair shedding (telogen effluvium) is reported by some patients ~3 months into rapid weight loss β typical of any rapid-weight-loss state, not unique to GLP-1. Full evidence-graded answer
- What foods should you avoid on a GLP-1?
- Avoid greasy, fried, and ultra-processed foods (worst nausea), high-sugar drinks (rapid reflux), and large portions of red meat or cruciferous vegetables (slow gastric emptying compounds GI side effects). Adequate protein + soluble fiber + hydration are the wins. Full evidence-graded answer
- How long do GLP-1 side effects last?
- Most GI side effects (nausea, constipation, reflux) peak in weeks 1-2 after each dose increase and resolve within 4 weeks. If you stay on a stable dose without further titration, side effects typically fade for β₯80% of patients by week 12. Full evidence-graded answer
- Does Ozempic cause stomach paralysis (gastroparesis)?
- GLP-1 medications delay gastric emptying as part of their mechanism β that is not stomach paralysis. True gastroparesis after GLP-1 use is rare and the absolute risk in pharmacovigilance data is small. Symptoms (severe nausea, vomiting, abdominal pain past week 8) warrant evaluation. Full evidence-graded answer
Editorial information based on FDA-label prevalence data + AERS pharmacovigilance + patient-reported outcome corpora. Not personal medical advice.